TY - JOUR
T1 - Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells
AU - Mahalingam, D.
AU - Natoni, A.
AU - Keane, M.
AU - Samali, A.
AU - Szegezdi, E.
N1 - Funding Information:
This work is supported by Cancer Research Ireland and Millennium Grant NUI Galway. The dominant-negative Egr-1 construct was a generous gift from Professor Gerald Thiel (University of Saarland Medical Center, Homburg, Germany) and the mitochondrion-localised Bcl-2 construct from Dr Peter Daniel (University of Berlin). We thank Aoife O’Reilly for her technical help.
PY - 2010/2
Y1 - 2010/2
N2 - Background: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour cell apoptosis by binding to death receptor 4 (DR4) and DR5. DR4 and DR5 activation however can also induce inflammatory and pro-survival signalling. It is not known how these different cellular responses are regulated and what the individual role of DR4 vs DR5 is in these processes. Methods:DNA microarray study was carried out to identify genes differentially expressed after DR4 and DR5 activation. RT-PCR and western blotting was used to examine the expression of early growth response gene-1 (Egr-1) and the proteins of the TRAIL signalling pathway. The function of Egr-1 was studied by siRNA-mediated knockdown and overexpression of a dominant-negative version of Egr-1.results: We show that the immediate early gene, Egr-1, regulates TRAIL sensitivity. Egr-1 is constitutively expressed in colon cancer cells and further induced upon activation of DR4 or DR5. Our results also show that DR4 mediates a type II, mitochondrion-dependent apoptotic pathway, whereas DR5 induces a mitochondrion-independent, type I apoptosis in HCT15 colon carcinoma cells. Egr-1 drives c-FLIP expression and the short splice variant of c-FLIP (c-FLIPS) specifically inhibits DR5 activation.Conclusion:Selective knockdown of c-FLIP S sensitises cells to DR5-induced but not DR4-induced apoptosis and Egr-1 exerts an effect as an inhibitor of the DR5-induced apoptotic pathway, possibly by regulating the expression of c-FLIP S.
AB - Background: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour cell apoptosis by binding to death receptor 4 (DR4) and DR5. DR4 and DR5 activation however can also induce inflammatory and pro-survival signalling. It is not known how these different cellular responses are regulated and what the individual role of DR4 vs DR5 is in these processes. Methods:DNA microarray study was carried out to identify genes differentially expressed after DR4 and DR5 activation. RT-PCR and western blotting was used to examine the expression of early growth response gene-1 (Egr-1) and the proteins of the TRAIL signalling pathway. The function of Egr-1 was studied by siRNA-mediated knockdown and overexpression of a dominant-negative version of Egr-1.results: We show that the immediate early gene, Egr-1, regulates TRAIL sensitivity. Egr-1 is constitutively expressed in colon cancer cells and further induced upon activation of DR4 or DR5. Our results also show that DR4 mediates a type II, mitochondrion-dependent apoptotic pathway, whereas DR5 induces a mitochondrion-independent, type I apoptosis in HCT15 colon carcinoma cells. Egr-1 drives c-FLIP expression and the short splice variant of c-FLIP (c-FLIPS) specifically inhibits DR5 activation.Conclusion:Selective knockdown of c-FLIP S sensitises cells to DR5-induced but not DR4-induced apoptosis and Egr-1 exerts an effect as an inhibitor of the DR5-induced apoptotic pathway, possibly by regulating the expression of c-FLIP S.
KW - Cellular FLICE inhibitory protein (c-FLIP)
KW - Colon carcinoma
KW - Death receptor 5 (DR5)
KW - Early growth response gene-1 (Egr-1)
KW - Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
KW - Type I extrinsic apoptotic pathway
UR - http://www.scopus.com/inward/record.url?scp=76949102583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76949102583&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6605545
DO - 10.1038/sj.bjc.6605545
M3 - Article
C2 - 20087343
AN - SCOPUS:76949102583
SN - 0007-0920
VL - 102
SP - 754
EP - 764
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 4
ER -